Merck Animal Health announced a $20,000 donation to the University of Nebraska–Lincoln Foundation (UNL) Klosterman Feedlot Innovation Center to support ongoing beef feedlot research initiatives. Merck Animal Health members recently visited the newly expanded UNL research feedlot to highlight the donation.
RAHWAY, N.J., November 6, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated $20,000 to the University of Nebraska–Lincoln Foundation (UNL) Klosterman Feedlot Innovation Center to support a sustainability-focused research initiative to better understand nutrient requirements for feedlot cattle.
The funds will support ongoing beef feedlot research initiatives at the Klosterman Feedlot Innovation Center. The donation will offset essential research costs and enhance the Center’s ability to deliver science-driven outcomes that inform a more efficient and sustainable beef industry.
“UNL’s mission to improve production efficiency, resource stewardship, and overall cattle wellbeing aligns closely with Merck Animal Health’s commitment to advancing animal health and sustainable food systems,” said John Hutcheson, director of beef technical services, Merck Animal Health. “We are proud to partner with the Klosterman Feedlot Innovation Center on this important work and believe the data generated will help inform practical solutions producers can adopt to conserve essential resources while maintaining cattle health and productivity.”
“Merck Animal Health’s generous support helps offset essential research costs and accelerates our ability to capture detailed, pen-level nutrient use,” said Jessica Sperber, Ph.D., assistant professor and beef feedlot specialist at UNL. “This partnership demonstrates Merck Animal Health’s leadership in supporting forward-thinking, science-based sustainability efforts in the beef industry. This donation better positions us to develop practical recommendations for producers that promote efficient nutrient use, animal wellbeing, and a resilient food system.”
The Klosterman Feedlot Innovation Center is a $7.2 million facility that facilitates world-class research projects, teaching and extension opportunities in a commercial-scale, state-of-the-art feedlot. The facility serves as a one-of-a-kind testbed where industry partners can see how new and emerging technologies work.
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
